Literature DB >> 17984088

Dual role of NRSF/REST in activation and repression of the glucocorticoid response.

Lilach Abramovitz1, Tamar Shapira, Iris Ben-Dror, Vardit Dror, Limor Granot, Tal Rousso, Elad Landoy, Lior Blau, Gerald Thiel, Lily Vardimon.   

Abstract

Restriction of glutamine synthetase to the nervous system is mainly achieved through the mutual function of the glucocorticoid receptor and the neural restrictive silencing factor, NRSF/REST. Glucocorticoids induce glutamine synthetase expression in neural tissues while NRSF/REST represses the hormonal response in non-neural cells. NRSF/REST is a modular protein that contains two independent repression domains, at the N and C termini of the molecule, and is dominantly expressed in nonneural cells. Neural tissues express however splice variants, REST4/5, which contain the repression domain at the N, but not at the C terminus of the molecule. Here we show that full-length NRSF/REST or its C-terminal domain can inhibit almost completely the induction of gene transcription by glucocorticoids. By contrast, the N-terminal domain not only fails to repress the hormonal response but rather stimulates it markedly. The inductive activity of the N-terminal domain is mediated by hBrm, which is recruited to the promoter only in the concomitant presence of GR. Importantly, a similar inductive activity is also exerted by the splice variant REST4. These findings raise the possibility that NRSF/REST exhibits a dual role in regulation of glutamine synthetase. It represses gene induction in nonneural cells and enhances the hormonal response, via its splice variant, in the nervous system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984088     DOI: 10.1074/jbc.M707366200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Estrogen coordinates translation and transcription, revealing a role for NRSF in human breast cancer cells.

Authors:  Michael W Bronson; Sara Hillenmeyer; Richard W Park; Alexander S Brodsky
Journal:  Mol Endocrinol       Date:  2010-04-14

2.  Tryptophan hydroxylase-2: an emerging therapeutic target for stress disorders.

Authors:  Guo-Lin Chen; Gregory M Miller
Journal:  Biochem Pharmacol       Date:  2013-02-19       Impact factor: 5.858

3.  REST and the RESTless: in stem cells and beyond.

Authors:  Vidya Gopalakrishnan
Journal:  Future Neurol       Date:  2009

4.  The transcription factor REST up-regulates tyrosine hydroxylase and antiapoptotic genes and protects dopaminergic neurons against manganese toxicity.

Authors:  Edward Pajarillo; Asha Rizor; Deok-Soo Son; Michael Aschner; Eunsook Lee
Journal:  J Biol Chem       Date:  2020-01-30       Impact factor: 5.157

5.  Desmosterol in brain is elevated because DHCR24 needs REST for Robust Expression but REST is poorly expressed.

Authors:  G S Tint; Luxing Pan; Quan Shang; Laura J Sharpe; Andrew J Brown; Man Li; Hongwei Yu
Journal:  Dev Neurosci       Date:  2014-05-24       Impact factor: 2.984

Review 6.  REST, a master transcriptional regulator in neurodegenerative disease.

Authors:  Jee-Yeon Hwang; R Suzanne Zukin
Journal:  Curr Opin Neurobiol       Date:  2018-01-30       Impact factor: 6.627

7.  Profiling RE1/REST-mediated histone modifications in the human genome.

Authors:  Deyou Zheng; Keji Zhao; Mark F Mehler
Journal:  Genome Biol       Date:  2009-01-27       Impact factor: 13.583

8.  Prenatal arsenic exposure alters REST/NRSF and microRNA regulators of embryonic neural stem cell fate in a sex-dependent manner.

Authors:  Christina R Tyler; Matthew T Labrecque; Elizabeth R Solomon; Xun Guo; Andrea M Allan
Journal:  Neurotoxicol Teratol       Date:  2016-10-14       Impact factor: 3.763

Review 9.  Brain REST/NRSF Is Not Only a Silent Repressor but Also an Active Protector.

Authors:  Yangang Zhao; Min Zhu; Yanlan Yu; Linli Qiu; Yuanyuan Zhang; Li He; Jiqiang Zhang
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

Review 10.  Epigenetics and epilepsy.

Authors:  Avtar Roopra; Raymond Dingledine; Jenny Hsieh
Journal:  Epilepsia       Date:  2012-12       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.